New evidence suggests tirzepatide reduces major cardiovascular events in type 2 diabetes patients

A recent study indicates that tirzepatide, a widely used diabetes and weight-loss medication, significantly lowers the risk of major cardiovascular events when added to standard care, potentially transforming treatment strategies for high-risk patients. A commonly used diabetes and weight-loss medicine,…













